TN2011000672A1 - Otamixaban for treatment of elderly and renal impaired non st-elevation myocardial patients - Google Patents

Otamixaban for treatment of elderly and renal impaired non st-elevation myocardial patients

Info

Publication number
TN2011000672A1
TN2011000672A1 TNP2011000672A TN2011000672A TN2011000672A1 TN 2011000672 A1 TN2011000672 A1 TN 2011000672A1 TN P2011000672 A TNP2011000672 A TN P2011000672A TN 2011000672 A TN2011000672 A TN 2011000672A TN 2011000672 A1 TN2011000672 A1 TN 2011000672A1
Authority
TN
Tunisia
Prior art keywords
elderly
treatment
otamixaban
elevation myocardial
impaired non
Prior art date
Application number
TNP2011000672A
Inventor
Jens Stechl
Angele Moryusef
Christophe Gaudin
Moury Pascale Ythier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/060615 external-priority patent/WO2011012527A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of TN2011000672A1 publication Critical patent/TN2011000672A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl) benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in non-ST elevation myocardial infarction, said treatment comprising administering a therapeutically effective amount of (2R,3R)-2-(3-Carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl) benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof to a human patient, who is elderly and/or shows renal insufficiency and/or has a low body weight.
TNP2011000672A 2009-07-29 2011-12-27 Otamixaban for treatment of elderly and renal impaired non st-elevation myocardial patients TN2011000672A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290601 2009-07-29
PCT/EP2010/060615 WO2011012527A1 (en) 2009-07-29 2010-07-22 Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients

Publications (1)

Publication Number Publication Date
TN2011000672A1 true TN2011000672A1 (en) 2013-05-24

Family

ID=41213432

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2011000672A TN2011000672A1 (en) 2009-07-29 2011-12-27 Otamixaban for treatment of elderly and renal impaired non st-elevation myocardial patients

Country Status (1)

Country Link
TN (1) TN2011000672A1 (en)

Similar Documents

Publication Publication Date Title
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
WO2012007159A3 (en) Novel gastro-retentive dosage forms
MX2011013902A (en) Treatment of multiple sclerosis with laquinimod.
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
NZ702801A (en) Treatment of sanfilippo syndrome type b
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
MY161078A (en) Topical formulation for a jak inhibitor
NZ605469A (en) Nalbuphine-based formulations and uses thereof
IN2014CN03234A (en)
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
IL217901B (en) Use of an amount of laquninimod or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a human subject suffering from a bdnf-related disease
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
TR201900199T4 (en) Immediate release pharmaceutical compositions containing oxycodone and naloxone.
MY173215A (en) Acetylcysteine compositions and methods of use thereof
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
EA201590166A8 (en) COMBINED THERAPY FOR THE TREATMENT OF SCATTERED SCLEROSIS
BR112013005673A2 (en) use of lysosomal acid lipase for treatment of lysosomal acid lipase deficiency in patients
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX2008013635A (en) Use of therapeutic human albumin for the preparation of a drug for the treatment of patients suffering from cognitive disorders.
NZ597957A (en) Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients
MX336278B (en) Compositions and methods for prevention and treatment of wounds.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX348723B (en) Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder.